Proliferative diabetic retinopathy therapy reshapes around anti-VEGF

Proliferative diabetic retinopathy has been a panretinal photocoagulation laser category for decades. Anti-VEGF therapy (ranibizumab, aflibercept) has become a first-line alternative or addition with substantial evidence supporting reduced visual acuity loss and reduced risk of severe vision-threatening complications, panretinal photocoagulation remains widely used (often combined or sequential with anti-VEGF), and emerging mechanism programs targeting alternative pathways are reading out. The diabetes-care-and-screening pathway integration is the addressable-population enabler.